Abbott Laboratories Com Stk NPV (NYSE:ABT)
Principal business is the discovery, development, manufacture and sale of a broad and diversified line of health care products. Company has four segments: Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Vascular Products.
- Quote
- Commentary
- Scorecard
- Historical Prices
- Chart
- Stats
- Ratios
- Earnings/Growth Rates
- Statements
- SEC Filings
Recs
sandrick
(60.06)
Submitted: 8/1/2009 12:11:12 AM :
Start Price:
$40.59
ABT Score:
-20.47
legal & contractual issues
Recs
Recs
Capsperson
(99.76)
Submitted: 7/14/2009 6:45:50 AM :
Start Price:
$41.84
ABT Score:
+1.92
Steady, solid performer with current P/E of 13.5. Business stays in noncontroversial products and proven performers. Long-term buy and hold.
Recs
STORMSTOCKER
(< 20)
Submitted: 7/7/2009 3:23:08 PM :
Start Price:
$40.61
ABT Score:
+3.46
THE BABY BOOMERS ARE AGING AND THEY ALL NEED HEALTHCARE, AND ABBOT LABS IS A MAJOR IN THE RANKS.
Recs
Alzo10
(98.32)
Submitted: 7/2/2009 7:48:02 AM :
Start Price:
$41.32
ABT Score:
+4.99
Cash flowing very nicely, and a company that has consistently beaten estimates while paying a nice dividend. This is an $80+ stock.
Recs
FlyingJib
(68.57)
Submitted: 6/28/2009 5:45:15 PM :
Start Price:
$42.47
ABT Score:
+2.49
One of the better pharmaceutical companies and they have a nice dividend!
Recs
cvelez73
(< 20)
Submitted: 6/7/2009 8:46:04 AM :
Start Price:
$39.84
ABT Score:
+14.01
Strong year over year growth, new medical optics division is huge and diabetes division just pumps out tons of margin.
Recs
kelsey2008
(40.39)
Submitted: 5/20/2009 9:47:52 PM :
Start Price:
$38.39
ABT Score:
+12.96
best pharma
Recs
TheBigLab
(< 20)
Submitted: 5/20/2009 2:29:49 AM :
Start Price:
$38.58
ABT Score:
+16.17
I think they will buy NNLX and add another billion+ dollars to the bottom line every year selling the BNP petri dishes for at least the next five years. Also, people will be getting and using more medical products now that they feel it will start to become affordable. Insurance companies will lose as ABT wins.
Recs
lemus
(84.35)
Submitted: 4/30/2009 2:30:51 PM :
Start Price:
$37.22
ABT Score:
+15.25
Great company with a lot of good products. Patents on their drugs are not near expiration, unlike some of their competitors. Nice dividend with a history of increases. I see no reason why this stock deserves to get beaten up as much as it has. Fears about Obama's healthcare reform are overblown.
Recs
luremoney
(81.77)
Submitted: 4/23/2009 12:32:35 PM :
Start Price:
$38.07
ABT Score:
+4.84
no comment This is a stock that is very likely to provide a 20%+ annual returns in the next 5 years
Recs
biggame2k2
(< 20)
Submitted: 4/18/2009 11:07:33 PM :
Start Price:
$39.03
ABT Score:
+3.46
company has great product trading at lows
Recs
petersenonetwo
(< 20)
Submitted: 4/18/2009 3:07:56 AM :
Start Price:
$39.03
ABT Score:
+3.46
Medical needs will improve with boomer retirement increases
Recs
TXinvestor82
(< 20)
Submitted: 4/16/2009 10:53:46 AM :
Start Price:
$37.93
ABT Score:
+6.98
Focus on long-term solutions, and a strong balance sheet as well. Got too tired of seeing this stock get beat up to resist any longer making it a pick of mine.
Recs
greenshooter
(38.62)
Submitted: 4/15/2009 9:18:13 PM :
Start Price:
$38.15
ABT Score:
+7.82
Humira shortfall is a temporary snag. It is actually gaining market share from Amgen and JNJ. Growth at good price after the Q1 call!
Recs
kenc132000
(96.22)
Submitted: 4/15/2009 1:43:54 PM :
Start Price:
$37.61
ABT Score:
+7.01
New 52 week low. Strong buy rating from S&P. Long time Cramer favorite. New position initiation.
Recs
00100
(97.73)
Submitted: 4/13/2009 7:55:50 PM :
Start Price:
$39.74
ABT Score:
-0.34
3/16/09 Pitch: Upthumb. Earnings 4/15/09. Money making machine. Core position. Recently increased dividend. Consistent positive standout in Barron's and Wall Street commentary. Could be posed for strong growth in 2009 and 2010.
Past Trades:
12/31/08 Upthumb. 1/21/2009 Earnings Day and day after Inauguration Day for President Obama. Believe that we will see large runup across the board from Dec 30 'til that day. Added Pitch on 01/10/09: Earnings 1/21/09, 9:00 AM Still think this is a good industry to be in during the recession. Closed 1/21/09 @ $52.32 for +6.84 points.
10/10/08 Upthumb. Earnings 10/15/08, 9:00 AM Good product pipeline, good industry to be in during recession. Closed 10/17/2008 @ $55.61 for +7.48 points.
Recs
spanxter
(< 20)
Submitted: 4/13/2009 4:31:17 PM :
Start Price:
$39.74
ABT Score:
-0.34
1. Abbott is trading near multiyear lows.
2. Abbott is a primary beneficiary of demographic driven growth in its secotr, and a new government focus to increase the amount of healthcare entitlement spending.
4. Abbott is a solid performer with broad leading positions in its sector. I believe Abbott's performance history warrants a contrarian view of recent news.
Recs
alfred13
(89.91)
Submitted: 4/9/2009 6:20:11 PM :
Start Price:
$39.14
ABT Score:
+1.84
I have watched this one make money from the sidelines for several years...just decided to get off the sidelines and own it. Performance has been consistent over the years, and very good.
Recs
bigbonesmagoo
(25.77)
Submitted: 4/8/2009 9:30:01 PM :
Start Price:
$38.30
ABT Score:
+0.53
Recent downgrade was a disgrace....stents are booming (perhaps best of class), smart management...Humira is a great product and don't see the slowing that prompted the downgrade....too cheap--should be trading at $55 minimum.
This is a conservative--nasty company--Miles White is a nasty SOB--just how I like them running my companies...
RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 181 - 200 of 344 : « Previous 5 6 7 8 9 10 11 12 13 14 Next »